Ana Jaén-Morago

Learn More
PURPOSE To assess the impact in pathological complete response (pCR) and outcome of two dose-dense neoadjuvant chemotherapy (DDNC) regimens among different histological subtypes determined by(More)
PURPOSE To study the role of breast cancer molecular subtypes according to hormone receptors and HER2 status as a predictive factor for pathological complete response (pCR) to neoadjuvant(More)
To the Editor: Neo-adjuvant chemotherapy is increasingly used in the management of early breast cancer. This strategy is indicated in patients with locally advanced breast cancer and has shown to(More)
PURPOSE To evaluate the pathologic complete response (pCR) rate of a combination of epirubicin (E) and cyclophosphamide (C) followed by paclitaxel (P) and gemcitabine (G) (+ trastuzumab[T]) in Her2+(More)
BACKGROUND To assess the molecular subtypes determined by hormonal receptors (HR) and human epidermal growth factor receptor 2 (HER2) status and the role of proliferation measured by the Ki-67 marker(More)
  • 1